Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
2024年5月6日 - 9:00PM
Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that
is reimagining therapeutic delivery, today announced that it will
present clinical data on device function of the NaviCap™ Targeted
Oral Delivery Platform at Digestive Disease Week® (DDW), which will
take place both virtually and in-person May 18-21, 2024 in
Washington, DC.
Details of the presentations are as follows:
Abstract Title: |
Results of
Human Device Function Studies for the NaviCap™ Targeted Oral
Delivery Platform in Healthy Volunteers and Patients with UC |
Poster No: |
Su1778 |
Session
Title: |
IBD: Controlled Clinical Trials in Humans |
Session Date &
Time: |
May 19, 2024 from 12:30 PM to 1:30 PM Eastern time |
Presenting
Author: |
Shaoying Nikki Lee, PhD, Director, Clinical and Translational
Science, Biora Therapeutics, Inc. |
Abstracts selected by the American Gastroenterological
Association (AGA) for presentation at DDW will be available in a
supplement to Gastroenterology. All information presented at DDW,
including poster presentations, is embargoed until 12:01 AM Eastern
on the day of the presentation. The poster presentation will be
made available on the Biora Therapeutics website following the
meeting.
About Digestive Disease WeekDigestive Disease
Week® (DDW) is the largest international gathering of physicians,
researchers and academics in the fields of gastroenterology,
hepatology, endoscopy and gastrointestinal surgery. Jointly
sponsored by the American Association for the Study of Liver
Diseases (AASLD), the American Gastroenterological Association
(AGA), the American Society for Gastrointestinal Endoscopy (ASGE)
and the Society for Surgery of the Alimentary Tract (SSAT), DDW is
an in-person and online meeting from May 18-21, 2024. The meeting
showcases more than 4,400 abstracts and hundreds of lectures on the
latest advances in GI research, medicine and technology. More
information can be found at www.ddw.org.
About the NaviCap™ Targeted Oral Delivery
Platform Biora's NaviCap targeted oral therapeutics
platform utilizes a novel approach that could improve patient
outcomes by enabling delivery of therapeutics directly to the site
of disease, increasing therapeutic levels in tissue while reducing
systemic uptake. For the 1.8 million patients in the United States
who suffer from inflammatory bowel disease (IBD), existing
therapeutics offer less than ideal efficacy, likely because of the
challenges with safely achieving sufficient drug levels in the
affected tissues. Research has shown that direct delivery
of therapeutics has the potential to improve patient outcomes in
IBD. The NaviCap platform uses an ingestible
device designed for direct delivery of therapeutics to improve
treatment of IBD. Once swallowed, Biora’s GItrac™ autolocation
technology enables the device to autonomously identify targeted
locations in the GI tract and release a therapeutic dose of up to
500µl. Studies in healthy volunteers have
demonstrated accurate localization and delivery in a fasted
state and demonstrated the device’s ability to function
in both fasted and fed states, making it potentially the first
ingestible therapeutic delivery device that does not require
fasting or other food restriction for use. A device function study
in participants with active UC also demonstrated successful device
performance in active UC patients.
About Biora TherapeuticsBiora Therapeutics is
reimagining therapeutic delivery. By creating innovative smart
pills designed for targeted drug delivery to the GI tract, and
systemic, needle-free delivery of biotherapeutics, the company is
developing therapies to improve patients’ lives.
Biora is focused on development of two therapeutics platforms:
the clinical-stage NaviCap™ targeted oral delivery platform, which
is designed to improve outcomes for patients with inflammatory
bowel disease through treatment at the site of disease in the
gastrointestinal tract, and the preclinical-stage BioJet™ systemic
oral delivery platform, which is designed to replace injection for
better management of chronic diseases through needle-free, oral
delivery of large molecules.
For more information, visit bioratherapeutics.com or follow the
company on LinkedIn or Twitter.
Safe Harbor Statement or Forward-Looking
StatementsThis press release contains “forward-looking
statements” within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995, which
statements are subject to substantial risks and uncertainties and
are based on estimates and assumptions. All statements, other than
statements of historical facts included in this press release,
including statements concerning the progress and future
expectations and goals of our research and development,
preclinical, and clinical trial efforts including our BT-600
clinical trial execution and data timelines, are forward-looking
statements. In some cases, you can identify forward-looking
statements by terms such as “may,” “might,” “will,” “objective,”
“intend,” “should,” “could,” “can,” “would,” “expect,” “forward,”
“believe,” “design,” “estimate,” “predict,” “potential,” “plan,”
“target,” or the negative of these terms, and similar expressions
intended to identify forward-looking statements. These statements
reflect our plans, estimates, and expectations, as of the date of
this press release. These statements involve known and unknown
risks, uncertainties and other factors that could cause our actual
results to differ materially from the forward-looking statements
expressed or implied in this press release. Such risks,
uncertainties, and other factors include, among others, our ability
to innovate in the field of therapeutics, our ability to make
future filings and initiate and execute clinical trials on expected
timelines or at all, our ability to obtain and maintain regulatory
approval or clearance of our products on expected timelines or at
all, our plans to research, develop, and commercialize new
products, the unpredictable relationship between preclinical study
results and clinical study results, our expectations regarding
allowed patents or intended grants to result in issued or granted
patents, our expectations regarding opportunities with current
or future pharmaceutical collaborators or partners, our ability to
raise sufficient capital to achieve our business objectives, and
those risks described in “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” in our Annual Report on Form 10-K for the year ended
December 31, 2023 filed with the SEC and other subsequent
documents, including Quarterly Reports, that we file with the
SEC.
Biora Therapeutics expressly disclaims any obligation to update
any forward-looking statements whether as a result of new
information, future events or otherwise, except as required by law.
Investor ContactChuck PadalaManaging Director,
LifeSci AdvisorsIR@bioratherapeutics.com(646) 627-8390
Media Contactmedia@bioratherapeutics.com
Biora Therapeutics (NASDAQ:BIOR)
過去 株価チャート
から 5 2024 まで 6 2024
Biora Therapeutics (NASDAQ:BIOR)
過去 株価チャート
から 6 2023 まで 6 2024